A Phase l Study of By101921, an Oral PARP7 Inhibitor, in Patients With Advanced Solid Tumors

NCT06433726 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

60

Enrollment

INDUSTRY

Sponsor class

Conditions

Solid Tumor, Adult

Interventions

DRUG: BY101921 tablets

Sponsor

Chengdu Baiyu Pharmaceutical Co., Ltd.